Epidemiologic and Clinical Features of Mpox-Associated Deaths — United States, May 10, 2022–March 7, 2023

Aspen P. Riser, MPH1,*; Allison Hanley, PhD1,2,*; Michael Cima, PhD3; Linda Lewis, DVM4; Kayla Saadeh, MPH4; Jemma Alarcón, MD2,5; Lauren Finn, MPH5; Moon Kim, MD5; Jeremy Adams, PhD6; Douglas Holt, MD6; Amanda Feldpausch, DVM7; Jessica Pavlick, DrPH7; Andrew English8; Marguerite Smith, MPH8; Tyler Rehman9; Ronald Lubelchek, MD10; Stephanie Black, MD11; Matthew Collins, MPH12; Layne Mounsey, MPH12; David Blythe, MD13; Meredith Hodach Avalos, MD14; Ellen H. Lee, MD15; Olivia Samson, MPH15; Marcia Wong, MD15; B. Denise Stokich16; Ellen Salehi, MPH17; Lynn Denny, MPH17; Kirsten Waller, MD18; Pamela Talley, MD19; Julie Schuman, MPH19; Michael Fischer, MD20; Stephen White, PhD20; Kenneth Davis20; Ashley Caeser Cuyler, MPH21; Rabeeya Sabzwari, MD22; Robert N. Anderson, PhD1; Katrina Byrd, MD1,2; Jeremy A. W. Gold, MD1; Shannon Kindilien, PhD1; James T. Lee, MD1; Siobhán O’Connor, MD1; Jesse O’Shea, MD1; LaTweika A. T. Salmon-Trejo, MPH1; Raquel Velazquez-Kronen, PhD1; Carla Zelaya, PhD1; William Bower, MD1; Sascha Ellington, PhD1; Adi V. Gundlapalli, MD, PhD1; Andrea M. McCollum, PhD1; Leah Zilversmit Pao, PhD1; Agam K. Rao, MD1; Karen K. Wong, MD1; Sarah Anne J. Guagliardo, PhD1 (View author affiliations)

View suggested citation


What is already known about this topic?

Severe manifestations of mpox have occurred in the United States, particularly among persons with uncontrolled viral spread resulting from moderately to severely immunocompromising conditions.

What is added by this report?

Thirty-eight mpox-associated deaths occurred in the United States during May 10, 2022–March 7, 2023 (1.3 mpox-associated deaths per 1,000 cases). Most decedents were non-Hispanic Black or African American (87%) persons and cisgender men (95%). Among 24 decedents with HIV for whom data were available, all had advanced HIV, typically with a CD4 count <50.

What are the implications for public health practice?

Equitable and early access to prevention and treatment for both mpox and HIV is critical to reducing mpox-related mortality.

Article Metrics

Views equals page views plus PDF downloads

Related Materials

As of March 7, 2023, a total of 30,235 confirmed and probable monkeypox (mpox) cases were reported in the United States, predominantly among cisgender men§ who reported recent sexual contact with another man (1). Although most mpox cases during the current outbreak have been self-limited, cases of severe illness and death have been reported (24). During May 10, 2022–March 7, 2023, 38 deaths among persons with probable or confirmed mpox (1.3 per 1,000 mpox cases) were reported to CDC and classified as mpox-associated (i.e., mpox was listed as a contributing or causal factor). Among the 38 mpox-associated deaths, 94.7% occurred in cisgender men (median age = 34 years); 86.8% occurred in non-Hispanic Black or African American (Black) persons. The median interval from symptom onset to death was 68 days (IQR = 50–86 days). Among 33 decedents with available information, 93.9% were immunocompromised because of HIV. Public health actions to prevent mpox deaths include integrated testing, diagnosis, and early treatment for mpox and HIV, and ensuring equitable access to both mpox and HIV prevention and treatment, such as antiretroviral therapy (ART) (5).

Data included in this report were collected during May 10, 2022–March 7, 2023. Jurisdictional health departments electronically reported confirmed and probable mpox cases and associated deaths as part of national case surveillance. Case data were shared with CDC through a standardized case report form or through the National Notifiable Diseases Surveillance System.** Additional data (e.g., clinical course, co-occurring health conditions, and treatments received) about some decedents were collected during consultations between treating clinicians and CDC clinical officers.†† Cause of death was most commonly determined by the treating health care provider and reported on the death certificate. Jurisdictional health departments shared cause-of-death data as reported on the death certificate to support classification of deaths. Deaths were classified as mpox-associated if mpox was listed on Part I or Part II of the death certificate (chain of events that directly caused the death or significant conditions contributing to death, respectively). Deaths were classified as non–mpox-associated if mpox was not listed on the death certificate, or if mpox appeared to be incidental to death. Deaths were classified as being under investigation§§ if jurisdictions were reviewing the cause-of-death with health care providers at the time of this analysis.

Descriptive statistics on demographics (e.g., age, gender identity, race and ethnicity, and state of residence) and clinical characteristics (i.e., treatments received and timing of treatments) were calculated for all patients with an mpox-associated death and were compared between decedents and patients who are presumed to have survived after confirmed or probable mpox (survivors). SAS statistical software (version 9.4; SAS Institute) was used for all analyses. This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.¶¶

CDC received reports of 52 deaths among persons with confirmed or probable mpox. Thirty-eight deaths (73.1%) were classified as mpox-associated, three (5.8%) were non–mpox-associated,*** and 11 (21.2%) deaths remain under investigation. Among the 38 mpox-associated deaths, 25 (65.8%) occurred during October–November 2022 (Figure).

The median age of decedents was 34 years (range = 22–58 years), and 36 (94.7%) were cisgender men (Table 1). A higher proportion of decedents than survivors were Black (86.8% versus 32.9%). Nearly one half of decedents (47.4%) resided in the U.S. Census Bureau South Region††† compared with 39.4% of survivors who lived in this region. Nine of the 10 decedents with recent sexual or intimate contact information had sexual or intimate contact with cisgender men in the 3 weeks preceding symptom onset. Two decedents reported nonsexual close contact exposures (e.g., co-sleeping and caring for a household member) to persons with mpox. Five of 11 decedents with available data were experiencing homelessness. Among 87% of decedents and 45% of survivors with available information, HIV infection was more prevalent among decedents than survivors (93.9% versus 38.3%).

Among 27 (71.0%) decedents with available clinical data, the median interval from symptom onset to death was 68 days (range = 1–146 days; IQR = 50–86 days), and 87.0% (20 of 23) were admitted to an intensive care unit during hospitalization (Table 2). Overall, 25 (92.6%) of 27 decedents with available treatment information received mpox-directed medical therapeutics§§§ at some point during their clinical care, including 25 who received tecovirimat, 18 of 24 who received vaccinia immunoglobulin intravenous (VIGIV), nine of 22 who received cidofovir, and six of 15 who received brincidofovir. Among the 25 decedents who received tecovirimat, 15 (60.0%) received it within 3 days of mpox diagnosis; however, for six (24.0%) decedents, tecovirimat was not administered until ≥3 weeks after diagnosis (median overall interval = 2 days; IQR = 0–20 days). Among 24 decedents with available data, all had lesions described as necrotic, diffuse, or worsened after a 14-day course of tecovirimat.

Two decedents did not receive any mpox therapeutics based on clinician discretion; in one case because of concerns regarding contraindication associated with other comorbidities. The other decedent was on ART for HIV with an undetectable viral load at the time of initial assessment for mpox care. Approximately 1 month later, at a wellness check, the patient was found deceased with diffuse lesions characteristic of mpox. Seven of 27 decedents for whom information was available refused therapeutic or intravenous medications or left the hospital against medical advice at some point during their clinical course of treatment. Among 24 decedents with information on receipt of steroids, more than one half (54.2%) received steroids for mpox complications or concerns about immune reconstitution inflammatory syndrome (IRIS), a hyperinflammatory response that can occur in patients with HIV during the first 6 months of ART (6).

Nearly all decedents with complete data on HIV infection were HIV-positive (93.9%; 31 of 33). Among 24 decedents with HIV and available data, all (100%) had CD4 counts <200 cells/mm3; 23 (95.8%) had CD4 counts <50 cells/mm3. Among the two immunocompromised decedents who did not have HIV, one was presumed to have been immunocompromised as a consequence of undiagnosed diabetes; the patient experienced diabetic ketoacidosis, a severe life-threatening complication of diabetes, at the time of mpox diagnosis. The second decedent was severely immunocompromised because of a recent renal transplant complicated by acute rejection.

Only two of the 25 persons with HIV (8.0%) reported taking ART before mpox diagnosis; in one of these decedents, HIV was poorly controlled. ART was initiated for 19 of the 20 decedents who were not receiving ART, including one decedent who received a diagnosis of HIV infection 5 days after the mpox diagnosis. One decedent refused treatment for advanced HIV. ART treatment status was not known for three of the 25 decedents with HIV. ART was either delayed or interrupted for seven decedents because of clinician concerns about IRIS.


During the 2022 mpox outbreak, 1.3 mpox-associated deaths per 1,000 cases occurred in the United States and approximately 1.2 deaths per 1,000 mpox cases occurred worldwide.¶¶¶ Nearly all U.S. mpox decedents were immunocompromised at the time of diagnosis. Almost 90% of U.S. mpox-associated deaths occurred in Black men, whereas fewer than one in three mpox survivors were Black men. Although mpox exposure data were not available for all decedents, nearly all cisgender male decedents who reported recent sexual contact reported cisgender male partners.

Most decedents received one or more prompt mpox-directed treatments and intensive care. However, nearly one quarter of decedents experienced delays of 3–7 weeks between diagnosis and treatment, and two patients did not receive any mpox-directed treatment. Before the 2022 mpox epidemic, severe cases mainly occurred in resource-constrained settings where transmission is endemic and where treatments, such as tecovirimat, cidofovir, and VIGIV, are not routinely available (6).

The lengthy course of illness experienced by most decedents is likely related to a reduced capacity to respond to infection because of co-occurring immunocompromise. When mpox is suspected, providers should consider early treatment with mpox-directed therapy, especially for patients with immunocompromising conditions who are at highest risk for severe outcomes.

The gender and racial disparities in mpox-associated deaths align with previous reports, in which most patients hospitalized for severe manifestations of mpox were Black men with uncontrolled HIV (4) and parallel racial and ethnic disparities in HIV infection and mortality. In 2020, 75% of all-cause deaths among adults with HIV occurred in males, 39% of whom were Black males.**** Disparities and barriers are apparent at all levels of HIV care including recognition of HIV risk, access to testing, and access to and receipt of preexposure prophylaxis and ART (7).

Most decedents with advanced HIV were not on ART at the time mpox was diagnosed. Boosting immune function via ART and avoidance of immunosuppressives, such as steroids, are critical to mpox recovery (6). ART was delayed or discontinued for several decedents because of concerns of IRIS, wherein a sudden improvement of immune function paradoxically worsens an infection. To date, no evidence exists indicating that IRIS contributes to poor mpox outcomes.

The Ending the HIV Epidemic initiative†††† has highlighted the need to address HIV transmission in the United States through response, prevention, diagnosis, and treatment efforts. All patients with suspected mpox should be evaluated for preexisting immunocompromising conditions such as HIV (7). Persons with diagnosed mpox who have HIV (even if newly diagnosed) who are not on ART should be started on ART as soon as possible. For persons who are HIV-negative, indications for HIV pre-exposure prophylaxis should be assessed.

Previous studies of mpox patients, in Nigeria, have documented anxiety, depression (8), and suicide (9). It has been suggested (9) that these outcomes resulted from stigma and the implications of acquiring a sexually associated infection, such as mpox, as well as the isolation experienced during prolonged treatment. Black and Hispanic or Latino males in the United States might face additional psychosocial pressures related to language barriers, homophobia, and discrimination (10). One suicide was noted among the decedents of non–mpox-associated deaths, and one decedent persistently declined treatment for HIV. These data highlight the need to strengthen psychosocial support services as part of the mpox epidemic response.

The findings in this report are subject to at least two limitations. First, deaths might be undercounted. Delays in reporting laboratory results, cases, and deaths are expected because reporting guidance was developed concurrently with the outbreak. Because reports from clinical consults were passively obtained, some deaths related to patients with mpox might not have been recorded. Second, some data (e.g., housing status, treatment, HIV status, and CD4 count) were more frequently available for decedents than for survivors because of additional reporting requirements for those who received intensive mpox treatments, thus limiting the comparisons between these two groups.

These findings highlight the importance of integrating prevention, testing, and treatment for multiple sexually associated infections (e.g., mpox and HIV, among others). Equitable access to prevention, treatment, and engagement and retention in care for both mpox and HIV should be prioritized, particularly among Black men and other persons at risk for sexually associated infections. These results underscore previous recommendations that providers offer HIV testing to all patients with probable or confirmed mpox and consider early mpox-directed treatment in highly immunocompromised patients (4,5,7). Further, combining therapies for mpox and boosting immune function might also reduce mortality from severe mpox (5).


Health care providers caring for mpox patients; public health responders from U.S. state and local departments of health; Isaac Ghinai, Janna L. Kerins, Massimo Pacilli, Hillary Spencer, Irina Tabidze, Chicago Department of Health; Rafael M. Mendoza, Jenniffer Rivas, Florida Department of Health in Broward County; Kristine Aviles, Florida Department of Health in Hillsborough County; Elizabeth Feinstone, Kristy Flom, Florida Department of Health in Osceola County; Madison Asbell, Cyndy Fohrman, Brenda Parduhn, Kira Richardson, Indiana Department of Health; Darby McDermott, Mojisola Ojo, Alex X. Zhang, New Jersey Department of Health; Courtney Dewart, CDC and Ohio Department of Health; Kara Tarter, Ohio Department of Health; Kevin Morris, Caleb Wiedeman, Tennessee Department of Health; Rania Milleron, Texas Department of State Health Services; Laura Bachmann, Adelaide Balenger, Denisse Descamps, Romeo R. Galang, Kaylea Nemechek, Suzanne Newton, Sheila Roy, Ruth Stefanos, CDC; CDC Clinical Escalations Team and health department personnel who consulted CDC for complicated cases of mpox; CDC clinical officers who perform consultations.

Corresponding author: Sarah Anne J. Guagliardo, sguagliardo@cdc.gov.

1Mpox Emergency Response Team, CDC; 2Epidemic Intelligence Service, CDC; 3Arkansas Department of Health; 4California Department of Health; 5Los Angeles County Department of Public Health, Los Angeles, California; 6Florida Department of Health; 7Georgia Department of Public Health; 8Illinois Department of Public Health; 9Department of Infectious Diseases, Loyola University Chicago, Chicago, Illinois; 10Cook County Department of Public Health, Forest Park, Illinois; 11Chicago Department of Public Health, Chicago, Illinois; 12Indiana Department of Health; 13Maryland Department of Health; 14New Jersey Department of Health; 15New York City Department of Health and Mental Hygiene, New York, New York; 16Nevada Department of Health and Human Services; 17Ohio Department of Health; 18Pennsylvania Department of Health; 19Tennessee Department of Health; 20Texas Department of State Health Services; 21Virginia Department of Health; 22Edward Hines Veterans Affairs Medical Center, Hines, Illinois.

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Siobhán O’Connor reports patent applications for kits and methods for determining physiologic levels, ranges of hemoglobin, or disease state, unrelated to this work. Meredith Hodach Avalos reports complementary attendance as a speaker at the March 2023 New Jersey American College of Physicians Conference, and medical staff membership in the Penn Medicine Princeton Medical Center. Pamela Talley reports payment by the state of Tennessee for hours spent collecting and reviewing data for Tennessee Department of Health’s two included mpox deaths. Stephen White reports uncompensated position of vice chair of the Global Health Committee of the Association of Public Health Laboratories. No other potential conflicts of interest were disclosed.

* These authors contributed equally to this report.

https://www.cdc.gov/poxvirus/mpox/response/2022/us-map.html (Accessed March 20, 2023).

§ Among mpox-associated deaths (38), data on gender identity was available for 28 (73.7%) decedents. For 10 (26.3%) persons for whom self-reported gender was missing, sex assigned at birth was substituted for gender identity.

Case counts include those who received a positive test result for either Monkeypox virus or orthopoxvirus.

** https://www.cdc.gov/nndss/index.html (Accessed March 20, 2023).

†† CDC provides clinical consultations upon request to jurisdictions and clinicians treating patients with mpox. Health care providers seeking additional clinical guidance can contact the CDC Emergency Operations Center by telephone (770-488-7100) or by email (eocevent482@cdc.gov).

§§ Discrepancies between laboratory reports and the cause of death as reported on the death certificate prompted three jurisdictions to seek clarification to reconcile the data.

¶¶ 45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq.

*** Causes of death included suicide and drug overdose.

††† https://www2.census.gov/geo/pdfs/maps-data/maps/reference/us_regdiv.pdf

§§§ Treatment classification includes report of tecovirimat (oral or intravenous), VIGIV, cidofovir, or brincidofovir in the clinical consultation data.

¶¶¶ https://www.cdc.gov/poxvirus/mpox/response/2022/world-map.html (Accessed March 5, 2023).

**** The number of deaths from all causes in patients with HIV infection was calculated using CDC’s Atlas Plus. https://gis.cdc.gov/grasp/nchhstpatlas/tables.html

†††† https://www.cdc.gov/endhiv/index.html


  1. Kava CM, Rohraff DM, Wallace B, et al. Epidemiologic features of the monkeypox outbreak and the public health response—United States, May 10–October 6, 2022. MMWR Morb Mortal Wkly Rep 2022;71:1449–56. https://doi.org/10.15585/mmwr.mm7145a4 PMID:36355615
  2. Menezes YR, Miranda AB. Severe disseminated clinical presentation of monkeypox virus infection in an immunosuppressed patient: first death report in Brazil. Rev Soc Bras Med Trop 2022;55:e0392. https://doi.org/10.1590/0037-8682-0392-2022 PMID:36037315
  3. Mitjà O, Alemany A, Marks M, et al. Mpox in people with advanced HIV infection: a global case series. Lancet 2023;401:939–49.. https://doi.org/10.1016/S0140-6736(23)00273-8
  4. Miller MJ, Cash-Goldwasser S, Marx GE, et al.; CDC Severe Monkeypox Investigations Team. Severe monkeypox in hospitalized patients—United States, August 10–October 10, 2022. MMWR Morb Mortal Wkly Rep 2022;71:1412–7. https://doi.org/10.15585/mmwr.mm7144e1 PMID:36327164
  5. O’Shea J, Filardo TD, Morris SB, Weiser J, Petersen B, Brooks JT. Interim guidance for prevention and treatment of monkeypox in persons with HIV infection—United States, August 2022. MMWR Morb Mortal Wkly Rep 2022;71:1023–8. https://doi.org/10.15585/mmwr.mm7132e4 PMID:35951495
  6. Rao AK, Schrodt CA, Minhaj FS, et al. Interim clinical treatment considerations for severe manifestations of mpox—United States, February 2023. MMWR Morb Mortal Wkly Rep 2023;72:232–43. https://doi.org/10.15585/mmwr.mm7209a4 PMID:36862595
  7. Bonacci RA, Smith DK, Ojikutu BO. Toward greater pre-exposure prophylaxis equity: increasing provision and uptake for Black and Hispanic/Latino individuals in the U.S. Am J Prev Med 2021;61(Suppl 1):S60–72. https://doi.org/10.1016/j.amepre.2021.05.027 PMID:34686293
  8. Ogoina D, Iroezindu M, James HI, et al. Clinical course and outcome of human monkeypox in Nigeria. Clin Infect Dis 2020;71:e210–4. https://doi.org/10.1093/cid/ciaa143 PMID:32052029
  9. Ogoina D, Mohammed A, Yinka-Ogunleye A, Ihekweazu C. A case of suicide during the 2017 monkeypox outbreak in Nigeria. IJID Reg 2022;3:226–7. https://doi.org/10.1016/j.ijregi.2022.04.004 PMID:35755463
  10. Mayer KH, Nelson L, Hightow-Weidman L, et al. The persistent and evolving HIV epidemic in American men who have sex with men. Lancet 2021;397:1116–26. https://doi.org/10.1016/S0140-6736(21)00321-4 PMID:33617771
Return to your place in the textFIGURE. Weekly confirmed and probable* mpox cases (A) and mpox-associated deaths (B),§ by week — United States, May 10, 2022—March 7, 2023
This figure is a set of two bar graphs showing the weekly confirmed and probable mpox cases and mpox-associated deaths, by week, in the United States, during May 10, 2022—March 7, 2023.

* https://www.cdc.gov/poxvirus/mpox/clinicians/case-definition.html

The earliest date available regarding the case, beginning with date of illness or rash onset, diagnosis date, positive laboratory test report date, CDC call center reporting date, or case data entry date into the National Notifiable Diseases Surveillance System.

§ Date of death as reported on the death certificate.

TABLE 1. Demographic and epidemiologic characteristics of persons who survived or died* from mpox-related illness — United States, May 10, 2022–March 7, 2023Return to your place in the text
Characteristic Mpox cases, no. (%)
(n = 30,183)
(n = 38)
Median age, yrs (range) 34 (0–89) 34 (22–58)
Sex or gender,§ total 26,082 (86.4) 38 (100.0)
Cisgender man 24,759 (94.9) 36 (94.7)
Cisgender woman 806 (3.1) 1 (2.6)
Transgender man 55 (0.2) 0 (—)
Transgender woman 227 (0.9) 1 (2.6)
Another gender identity 235 (0.9) 0 (—)
Unknown 4,101 0
Race and ethnicity, total 28,233 (93.5) 38 (100.0)
American Indian or Alaska Native, non-Hispanic 115 (0.4) 0 (—)
Asian, non-Hispanic 786 (2.8) 0 (—)
Black or African American, non-Hispanic 9,295 (32.9) 33 (86.8)
Native Hawaiian or other Pacific Islander, non-Hispanic 68 (0.2) 0 (—)
White, non-Hispanic 8,277 (29.3) 3 (7.9)
Hispanic or Latino 8,849 (31.3) 2 (5.3)
Other race, non-Hispanic 668 (2.4) 0 (—)
Multiple races, non-Hispanic 175 (0.6) 0 (—)
Unknown 1,950 0
U.S. Census Bureau region, total 30,183 (100.0) 38 (100.0)
Northeast 6,600 (21.9) 6 (15.8)
Midwest 3,164 (10.5) 9 (23.7)
South 11,882 (39.4) 18 (47.4)
West 8,330 (27.6) 5 (13.2)
Puerto Rico 207 (0.7) 0 (—)
Experiencing homelessness NA 11 (40.7)
Yes NA 5 (45.5)
No NA 6 (54.5)
Unknown 30,183 16
Sexual or intimate contact in the 3 wks before symptom onset 18,385 (60.9) 16 (42.1)
Sexual contact in the past 3 wks 15,061 (81.9) 10 (62.5)
Recent partners exclusively men 12,759 (69.4) 9 (56.2)
Recent partners women or other genders (no men) 898 (4.9) 0 (—)
Recent partners include men and other genders 503 (2.7) 0 (—)
Gender of all partners unknown/Not specified 901 (4.9) 1 (6.3)
No recent sexual contact 3,324 (18.1) 6 (37.5)
Unknown 11,798 22
Interval from illness onset to testing, days, median (IQR)** 7 (4–10) 7 (3–10)
HIV-positive or immunocompromised†† 13,549 (44.9) 33 (86.8)
Yes, HIV-positive 5,186 (38.3) 31 (93.9)
Yes, other immunocompromising conditions 654 (4.8) 2 (9.1)
No 7,709 (56.9) 0 (—)
Unknown 16,634 5
Received JYNNEOS vaccine§§ 11,316 (37.5) 13 (34.2)
Yes 8,238 (72.8) 1 (7.7)
No 3,078 (27.2) 12 (92.3)
Unknown 18,867 25

Abbreviation: NA = not available.
* Mpox was listed as directly causing or significantly contributing to death on the death certificate.
Percentages were calculated with nonmissing data.
§ Among decedents whose death was mpox-associated (38), self-reported data on gender identity was available for 28 (73.7%) decedents. Sex assigned at birth was substituted for 10 (26.3%) decedents for whom gender identity was missing.
https://www2.census.gov/geo/pdfs/maps-data/maps/reference/us_regdiv.pdf (Accessed March 24, 2023). Puerto Rico is not included in any U.S. Census Bureau region.
** Illness onset is the date any reported symptoms first started.
†† Non-HIV immunocompromising conditions included renal transplant (one) and uncontrolled diabetes (one).
§§ At least 1 dose.

TABLE 2. Selected clinical characteristics* of mpox-associated deaths with available clinical data (N = 27) — United States, May 10, 2022–March 7, 2023Return to your place in the text
Characteristic (no. with information) Mpox-associated deaths, no. (%)
Days from symptom onset to death (26), median (IQR) 68 (50–86)
Admitted to ICU 23 (85.2)
Yes 20 (87.0)
No 3 (13.0)
Unknown 4
Medical treatment§
Received any mpox-directed treatment 27 (100.0)
Yes 25 (92.6)
No 2 (7.4)
Unknown 0
Days from first mpox treatment date to death (21), median (IQR) 58 (32–66)
Specific mpox-directed treatment received
Tecovirimat 27 (100.0)
Yes 25 (92.6)
No 2 (7.4)
Unknown 0
Interval from mpox diagnosis to initiation of tecovirimat treatment (20), days, median (IQR) 2 (0–20)
VIGIV 24 (88.9)
Yes 18 (75.0)
No 6 (25.0)
Unknown 3
Cidofovir 22 (81.5)
Yes 9 (40.9)
No 13 (59.1)
Unknown 5
Brincidofovir 15 (55.6)
Yes 6 (40.0)
No 9 (60.0)
Unknown 12
Necrotic, diffuse, or worsened lesions 24 (88.9)
Yes 24 (100.0)
No 0 (—)
Unknown 3
Received steroids for mpox complications or IRIS concerns 24 (88.9)
Yes 13 (54.2)
No 11 (45.8)
Unknown 3
HIV-positive or immunocompromised** 27 (100.0)
HIV-positive 25 (92.6)
CD4 ≥500 0 (—)
CD4 ≥200 to <500 0 (—)
CD4 ≥50 to <200 1 (4.2)
CD4 <50 23 (95.8)
CD4 Unknown 1
Immunocompromised (HIV-negative) 2 (7.4)
Unknown 0
Receiving ART (HIV-positive persons) 22 (88.0)
Yes, before mpox diagnosis 2 (9.1)
Yes, after mpox diagnosis 19 (86.4)
No, refused 1 (4.5)
Unknown 3
Interval from mpox diagnosis to initiation of ART (9), days, median (IQR) 15 (5–26)

Abbreviations: ART = antiretroviral treatment; ICU = intensive care unit; IRIS = immune reconstitution inflammatory syndrome; VIGIV = vaccinia immune globulin intravenous.
* Reported or collected during clinical consult with treating physician.
Percentages calculated with nonmissing data. Percentages calculated based on total number in each subgroup.
§ Treatment classification includes report of tecovirimat (oral or intravenous), VIGIV, cidofovir, or brincidofovir in the clinical consultation data.
Reported during clinical consultation with treating physician or through expert assessment of photographs.
** Non-HIV immunocompromising conditions included renal transplant (one) and uncontrolled diabetes (one).

Suggested citation for this article: Riser AP, Hanley A, Cima M, et al. Epidemiologic and Clinical Features of Mpox-Associated Deaths — United States, May 10, 2022–March 7, 2023. MMWR Morb Mortal Wkly Rep 2023;72:404–410. DOI: http://dx.doi.org/10.15585/mmwr.mm7215a5.

MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.

Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.